JP7430656B2 - Ｃｄｋ４／６活性阻害化合物の結晶形およびその使用 - Google Patents

Ｃｄｋ４／６活性阻害化合物の結晶形およびその使用 Download PDF

Info

Publication number
JP7430656B2
JP7430656B2 JP2020571503A JP2020571503A JP7430656B2 JP 7430656 B2 JP7430656 B2 JP 7430656B2 JP 2020571503 A JP2020571503 A JP 2020571503A JP 2020571503 A JP2020571503 A JP 2020571503A JP 7430656 B2 JP7430656 B2 JP 7430656B2
Authority
JP
Japan
Prior art keywords
crystalline form
compound
cancer
powder
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020571503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529175A (ja
JP2021529175A5 (https=
JPWO2019242719A5 (https=
Inventor
義乾 王
春輝 張
家炳 王
列明 丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of JP2021529175A publication Critical patent/JP2021529175A/ja
Publication of JP2021529175A5 publication Critical patent/JP2021529175A5/ja
Publication of JPWO2019242719A5 publication Critical patent/JPWO2019242719A5/ja
Application granted granted Critical
Publication of JP7430656B2 publication Critical patent/JP7430656B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020571503A 2018-06-21 2019-06-21 Ｃｄｋ４／６活性阻害化合物の結晶形およびその使用 Active JP7430656B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/092194 2018-06-21
CN2018092194 2018-06-21
PCT/CN2019/092239 WO2019242719A1 (zh) 2018-06-21 2019-06-21 抑制cdk4/6活性化合物的晶型及其应用

Publications (4)

Publication Number Publication Date
JP2021529175A JP2021529175A (ja) 2021-10-28
JP2021529175A5 JP2021529175A5 (https=) 2022-06-22
JPWO2019242719A5 JPWO2019242719A5 (https=) 2022-06-22
JP7430656B2 true JP7430656B2 (ja) 2024-02-13

Family

ID=68983152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020571503A Active JP7430656B2 (ja) 2018-06-21 2019-06-21 Ｃｄｋ４／６活性阻害化合物の結晶形およびその使用

Country Status (14)

Country Link
US (1) US12043622B2 (https=)
EP (1) EP3812386A4 (https=)
JP (1) JP7430656B2 (https=)
KR (1) KR102768666B1 (https=)
CN (2) CN112424202B (https=)
AU (1) AU2019290722B2 (https=)
BR (1) BR112020026052A2 (https=)
EA (1) EA202190036A1 (https=)
IL (1) IL279579B2 (https=)
MX (1) MX2020013847A (https=)
PH (1) PH12020552236A1 (https=)
SG (1) SG11202012858QA (https=)
TW (1) TWI786303B (https=)
WO (1) WO2019242719A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117222411B (zh) * 2021-03-24 2026-03-27 贝达药业股份有限公司 药物组合、包含其的试剂盒及其用途
WO2023131179A1 (zh) * 2022-01-05 2023-07-13 贝达药业股份有限公司 苯并咪唑衍生物或其盐在治疗白血病中的用途
CN115872923B (zh) * 2022-12-29 2023-04-28 成都泰和伟业生物科技有限公司 一种化合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN107849012A (zh) 2015-04-28 2018-03-27 重庆复创医药研究有限公司 一类激酶抑制剂
JP2020504747A (ja) 2016-12-22 2020-02-13 貝達薬業股▲ふん▼有限公司Ｂｅｔｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．，Ｌｔｄ ベンズイミダゾール誘導体、調製方法およびそれらの使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294655B (zh) 2014-07-26 2019-03-15 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
CN104592251B (zh) 2015-01-23 2019-10-01 上海复星医药产业发展有限公司 4-(稠杂环取代氨基)-1h-吡唑-3-甲酰胺类化合物及其用途
WO2017005900A1 (en) 2015-07-08 2017-01-12 F. Hoffmann-La Roche Ag ARYL SULTAM DERIVATIVES AS RORc MODULATORS
WO2017102796A1 (en) 2015-12-16 2017-06-22 F. Hoffmann-La Roche Ag HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS
TWI646094B (zh) 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
WO2019035008A1 (en) 2017-08-15 2019-02-21 Beijing Xuanyi Pharmasciences Co., Ltd. INHIBITORS OF CDK4 / 6 AND THEIR USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849012A (zh) 2015-04-28 2018-03-27 重庆复创医药研究有限公司 一类激酶抑制剂
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
JP2020504747A (ja) 2016-12-22 2020-02-13 貝達薬業股▲ふん▼有限公司Ｂｅｔｔａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．，Ｌｔｄ ベンズイミダゾール誘導体、調製方法およびそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters，2018年，Vol. 28, No. 5，p. 974-978

Also Published As

Publication number Publication date
EP3812386A4 (en) 2022-03-30
IL279579A (en) 2021-03-01
CA3104365A1 (en) 2019-12-26
JP2021529175A (ja) 2021-10-28
EP3812386A1 (en) 2021-04-28
BR112020026052A2 (pt) 2021-03-23
AU2019290722B2 (en) 2023-12-21
IL279579B (en) 2022-10-01
IL279579B2 (en) 2023-02-01
KR102768666B1 (ko) 2025-02-17
CN113861191A (zh) 2021-12-31
KR20210024004A (ko) 2021-03-04
CN112424202A (zh) 2021-02-26
PH12020552236A1 (en) 2021-06-28
TW202016114A (zh) 2020-05-01
CN113861191B (zh) 2023-09-19
US12043622B2 (en) 2024-07-23
MX2020013847A (es) 2021-04-28
AU2019290722A1 (en) 2021-01-28
TWI786303B (zh) 2022-12-11
CN112424202B (zh) 2021-09-17
WO2019242719A1 (zh) 2019-12-26
SG11202012858QA (en) 2021-02-25
US20210261546A1 (en) 2021-08-26
EA202190036A1 (ru) 2021-03-24

Similar Documents

Publication Publication Date Title
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
US10793543B2 (en) Selective C-KIT kinase inhibitor
CN107922417B (zh) 蝶啶酮衍生物作为egfr抑制剂的应用
JP2011515370A (ja) ４−アミノ−５−フルオロ−３−［５−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］キノリン−２（１ｈ）−オン乳酸塩の結晶形態及び２つの溶媒和物形態
JP2019526605A (ja) 置換２−ｈ−ピラゾール誘導体の結晶形、塩型及びその製造方法
JP7430656B2 (ja) Ｃｄｋ４／６活性阻害化合物の結晶形およびその使用
EP3590941A1 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
US10865198B2 (en) Solid forms of cerdulatinib
WO2023093859A1 (zh) Axl激酶抑制剂的盐、其制备方法和用途
CN104119321B (zh) 二氢吲哚酮衍生物的二马来酸盐及其多晶型物
KR20220159457A (ko) Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도
CA3104365C (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
HK40037648A (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
HK40037648B (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
CN120289432B (zh) 一种具有极光激酶b和表皮生长因子受体双重抑制作用的喹啉类化合物及用途
EA043251B1 (ru) Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение
CN112654623B (zh) 新型氮杂三环类化合物的盐型、晶型及其用途
TW201125861A (en) CDC7 inhibitor salts
WO2021249450A1 (zh) 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途
WO2014141118A1 (en) Imidazo[4,5-c]quinoline derivatives and uses thereof

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220614

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240131

R150 Certificate of patent or registration of utility model

Ref document number: 7430656

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150